Home
About Us
Clinical Trials
Science & Technology
Pipeline
Investor Relations
Resources
Patient Resources
Contact

ALS drug failures and why COYA 302 is different

March 8, 2025

Share this post

We are a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells. We are currently developing our multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.

Links

About Us
Clinical Trials
Investor Relations
Patient Resources
Pipeline
Resources
Science & Technology

About Us
Clinical Trials
Investor Relations
Patient Resources
Pipeline
Resources
Science & Technology

Linkedin Youtube Twitter

Contact Us

5850 San Felipe St., Suite 500 Houston, TX 77057 USA

+1 800-587-8170

Contact Us

Privacy Policy
Terms & Conditions

Biotech Website Design